<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7241406\results\search\testTrace\results.xml">
  <result pre="The eye as the discrete but defensible portal of coronavirus" exact="infection" post="CoroneoMinas Theodorem.coroneo@unsw.edu.auabâˆ—[a], [b], âˆ—Department of Ophthalmology, Prince of Wales"/>
  <result pre="a highly contagious, potentially lethal, virus with ocular tropism. Respiratory" exact="infection" post="transmission via the eye and lacrimal-nasal pathway elucidated during"/>
  <result pre="[1], was Dr Li Wenliang, an ophthalmologist, who died following" exact="infection" post="with COVID-19 [2,3]. It was thought he was infected"/>
  <result pre="2â€&quot;3Â h, slower than might be expected from older studies" exact="tracing" post="the passage of bacteria through the lacrimal drainage system"/>
  <result pre="[5]. While an N95 respirator was worn, offering protection from" exact="infection" post="via oro-nasal pathways, eye protection was not. Evidence that"/>
  <result pre="of COVID-19? Dr Li Wenliang's death and the apparent high" exact="infection" post="rate in ophthalmologists (and ENT surgeons) [11], attributed to"/>
  <result pre="of ~28â€&quot;30Â cm. This proximity and the possibility of cross" exact="infection" post="between examiner and examinee has long been recognized and"/>
  <result pre="slit lamps and their accessory lenses are a source of" exact="infection" post="transmission has long been known [15]. In epidemic adenoviral"/>
  <result pre="provided information as to the permissiveness of ocular tissue to" exact="infection" post="with these agents [6,36]. Central to COVID-19 pathogenicity is"/>
  <result pre="of likely sustained SARS-CoV-2 replication in three patients with systemic" exact="infection" post="and conjunctivitis [[57], [58], [59]]. While it was found"/>
  <result pre="the tear film may protect the ocular surface from epithelial" exact="infection" post="and convey virus downstream. The nasolacrimal system, via the"/>
  <result pre="inhibitors and chloroquine. ACE inhibitors are widely used in the" exact="treatment" post="of systemic diseases including hypertension and are generally well"/>
  <result pre="effects that result in increased disease severity when in vitro" exact="testing" post="alone might suggest efficacy [85]. Table 2 Proposed Agents"/>
  <result pre="studies. aFor SARS-CoV. Chloroquine has long been used in the" exact="treatment" post="of malaria and subsequently, autoimmune disorders (such as rheumatoid"/>
  <result pre="retroviruses, and coronaviruses [86], exhibiting strong antiviral effects on coronavirus" exact="infection" post="of primate cells [72,87]. The drug can be effective"/>
  <result pre="been reported [94] and this may be exacerbated by combination" exact="treatment" post="with azithromycin [74]. The well-known association with irreversible visual"/>
  <result pre="polymerase activity [101], blocking viral replication. For this reason, combination" exact="treatment" post="for Covid-19 with chloroquine and zinc has been suggested"/>
  <result pre="intervention has yet to be formally reported. Possibility of topical/local" exact="treatment" post="for SARS-CoV-2 It is perhaps unsurprising, given the passage"/>
  <result pre="have suggested that hypertension may be a risk factor for" exact="infection" post="but these are unconfirmed [107]. Azithromycin has also previously"/>
  <result pre="orders of magnitude higher than plasma levels (reached with systemic" exact="treatment" post="[108]) could be achieved. Conclusion At this point, clinical"/>
  <result pre="systemic treatment. A spray or aerosol preparation would also allow" exact="treatment" post="of the nasal passages [45] and mouth [109], given"/>
  <result pre="oculotropic, this may be superfluous. If a patient has active" exact="infection" post="of the respiratory tree, then this combined medication could"/>
  <result pre="The ocular surface, offering all of the benefits of local" exact="treatment" post="familiar to ophthalmologists, may thus provide a convenient testing"/>
  <result pre="local treatment familiar to ophthalmologists, may thus provide a convenient" exact="testing" post="ground for rapid, safe and likely cost-effective trials of"/>
  <result pre="competing interest The author has filed patent applications on the" exact="treatment" post="methods and concerning slit lamp design, described in this"/>
  <result pre="the ocular surface must not be ignoredLancet395102242020e3932035510 5MaxcyK.F.The transmission of" exact="infection" post="through the eyeJ Am Med Assoc721919636639 6BelserJ.A.RotaP.A.TumpeyT.M.Ocular tropism of"/>
  <result pre="virusesMicrobiol Mol Biol Rev77201314415623471620 7BelserJ.A.LashR.R.GargS.TumpeyT.M.MainesT.R.The eyes have it: influenza virus" exact="infection" post="beyond the respiratory tractLancet Infect Dis182018e220e22729477464 8BelserJ.A.DavisC.T.BalishA.EdwardsL.E.ZengH.MainesT.R.GustinK.M.MartÃ­nezI.L.FasceR.CoxN.J.KatzJ.M.TumpeyT.M.Pathogenesis, transmissibility, and"/>
  <result pre="self-report occupational complaints among Iranian ophthalmologists: a preliminary surveyMedGenMed6420041 18QaderU.J.A.The" exact="prevalence" post="of adenoviral conjunctivitis in Tikrit district and the role"/>
  <result pre="of cosmetic products into the tear filmEye Contact Lens41201530430925738987 30MacKeenD.L.RothH.W.DoaneM.G.MacKeenP.D.Supracutaneous" exact="treatment" post="of dry eye patients with calcium carbonateAdv Exp Med"/>
  <result pre="dry eye patients with calcium carbonateAdv Exp Med Biol43819989859909634999 31TsubotaK.MondenY.YagiY.GotoE.ShimmuraS.New" exact="treatment" post="of dry eye: the effect of calcium ointment through"/>
  <result pre="Pathol203200463163715141377 43JiaH.P.LookD.C.ShiL.ACE2 receptor expression and severe acute respiratory syndrome coronavirus" exact="infection" post="depend on differentiation of human airway epitheliaJ Virol792005146141462116282461 44SavaskanE.LÃ¶fflerK.U.MeierF.MÃ¼ller-SpahnF.FlammerJ.MeyerP.Immunohistochemical"/>
  <result pre="Virol2020 Feb 2610.1002/jmv.25725[Epub ahead of print] [PMID: 32100876] doi: 58ColavitaF.LapaD.CarlettiF.SARS-CoV-2" exact="isolation" post="from ocular secretions of a patient with COVID-19 in"/>
  <result pre="review of clinical trials utilizing chloroquine and hydroxychloroquine as a" exact="treatment" post="for COVID-19Acad Emerg Med2020 May 210.1111/acem.14005.Mar9:ciaa237 75BhavsarAnkita SamirBhavsarSamir G.JainSunita"/>
  <result pre="1710.1002/cpt.1857 78OpitzD.L.HarthanJ.S.Review of azithromycin ophthalmic 1% solution (AzaSite(Â®)) for the" exact="treatment" post="of ocular infectionsOphthalmol Eye Dis4201211423650453 79AmzaA.GoldschmidtP.EinterzE.Elimination of active trachoma"/>
  <result pre="Infect Dis3200372272714592603 87VincentM.J.BergeronE.BenjannetS.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol J220056916115318 88KeyaertsE.VijgenL.MaesP.NeytsJ.Van RanstM.In vitro inhibition of severe"/>
  <result pre="and projection of optimized dosing design of hydroxychloroquine for the" exact="treatment" post="of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin Infect"/>
  <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitroCell Discovery62020161932194981 93GautretP.LagierJ.C.ParolaP.Clinical and microbiological effect of a"/>
 </snippets>
</snippetsTree>
